VA
CYTK icon

Vident Advisory’s Cytokinetics CYTK Stock Holding History

Vident Advisory’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.35M Sell
15,898
-1,171
-7% -$84.1K 0.01% 832
2026
Q1 		$1.13M Buy
17,069
+614
+4% +$39K 0.01% 828
2025
Q4 		$1.05M Buy
16,455
+234
+1% +$14.6K 0.01% 786
2025
Q3 		$892K Buy
+16,221
New +$668K 0.01% 881
2024
Q4 		– Sell
-4,195
Closed -$221K – 1473
2024
Q3 		$221K Buy
+4,195
New +$234K 0.01% 1270

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vident Advisory's CYTK Position: Q2 2026 in Review

Vident Advisory reduced its Cytokinetics (CYTK) stake by 6.9% in Q2 2026, selling an estimated $84.1K and leaving 15,898 shares worth $1.35M. The position accounts for 0.01% of the portfolio, ranked #832.

Vident Advisory first reported a position in CYTK in Q3 2024 and has held it in 5 quarters since. 484 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Vident Advisory held 15,898 shares of Cytokinetics worth $1.35M as of Q2 2026.
  • Vident Advisory sold 1,171 Cytokinetics shares in Q2 2026, an estimated $84.1K.
  • Cytokinetics made up 0.01% of Vident Advisory's portfolio in Q2 2026, its #832 holding.
  • Vident Advisory first reported a position in Cytokinetics in Q3 2024 and has held it in 5 quarters since.
  • 484 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.